Infectious Enteritis Treatment Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

The infectious enteritis treatment market share is expected to increase by USD 403.92 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.09%. This infectious enteritis treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The infectious enteritis treatment market report also offers information on several market vendors, including Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. among others. Furthermore, this report extensively covers infectious enteritis treatment market segmentation by route of administration (oral and injectables) and geography (North America, Europe, Asia, and Rest of World (ROW)).

What will the Infectious Enteritis Treatment Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Infectious Enteritis Treatment Market Size for the Forecast Period and Other Important Statistics

 

Infectious Enteritis Treatment Market: Key Drivers, Trends, and Challenges

The increasing geriatric population is notably driving the infectious enteritis treatment market growth, although factors such as adverse effects associated with infectious enteritis treatment may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the infectious enteritis treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Infectious Enteritis Treatment Market Driver

One of the key factors driving the global infectious enteritis treatment market growth is the increasing geriatric population in countries, such as Japan, Italy, and the US. For instance, according to the United Nations (UN) Department of Economic and Social Affairs, the population division of the geriatric population (persons aged 65 or over) was 702.9 million in 2019, which will become 727 million in 2020. Similarly, the geriatric population in India will increase by 41% over the next decade to touch 194 million in 2031. This increase in the percentage of the geriatric population around the globe is increasing the demand for the treatment of hospital-acquired infections around the world, which will work as a driver for the infectious enteritis treatment market during the forecast period.

Key Infectious Enteritis Treatment Market Trend

Burgeoning demand for antivirals is one of the key infectious enteritis treatment market trends that is expected to impact the industry positively in the forecast period. One can treat viral gastroenteritis by replacing lost fluids and electrolytes to prevent dehydration. In some cases, over-the-counter (OTC) drugs, such as loperamide (Imodium) and bismuth subsalicylate (Pepto-Bismol, Kaopectate), may also help relieve the symptoms due to viral gastroenteritis. Moreover, doctors also avoid prescribing antibiotics to treat viral gastroenteritis since antibiotics are not efficient against viral infections. As of now, two vaccines, which infants receive by mouth, are approved to protect against rotavirus infections, i.e., RotaTeq and Rotarix. Such factors are expected to support the market growth in the coming years.

Key Infectious Enteritis Treatment Market Challenge

One of the key challenges to the global infectious enteritis treatment market growth is the adverse effects associated with infectious enteritis treatment. Infectious enteritis causes diarrhea and associated fluid and electrolyte losses. Maldigestion and malabsorption are the dominant underlying pathophysiologic mechanisms; hence, intravenous therapy is more effective (at least initially) at correcting the electrolyte imbalances and fluid loss compared with oral administration. The crystalloids and colloids fluids should be considered as part of the fluid therapy. However, sometimes the treatment of infectious enteritis with these fluids or any other medication such as penicillin, cephalosporin, antifolate or sulfa combinations, nitroimidazole, glycopeptide, and monobactam antibiotics would further cause various side effects due to the historic allergy of the patients. Such factors are expected to negatively impact the market growth during the forecast period.

This infectious enteritis treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global infectious enteritis treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the infectious enteritis treatment market during the forecast period.

Who are the Major Infectious Enteritis Treatment Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Abbott Laboratories
• Almirall SA
• Cipla Ltd.
• Zydus Lifesciences Ltd.
• F. Hoffmann La Roche Ltd.
• Galderma SA
• GlaxoSmithKline Plc
• Hetero Healthcare Ltd.
• Mayne Pharma Group Ltd.
• Medimetriks Pharmaceuticals Inc.
• Merck KGaA
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Tolmar Pharmaceuticals Inc.
• Viatris Inc.

 

This statistical study of the infectious enteritis treatment market encompasses successful business strategies deployed by the key vendors. The infectious enteritis treatment market is fragmented and the vendors are deploying growth strategies such as geographical expansion, product portfolio expansion, and product innovation to compete in the market.

Product Insights and News

• Abbott Laboratories is a public company headquartered in the US. It is a global company generating USD 43,075 million in revenues and has around 113,000 employees. Its revenue from the global infectious enteritis treatment market contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company. 
• The company offers products such as ENOXABID

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The infectious enteritis treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Infectious Enteritis Treatment Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the infectious enteritis treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Infectious Enteritis Treatment Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for infectious enteritis treatment in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).

The significant increase in foodborne illnesses in countries such as the US will facilitate the infectious enteritis treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Route Of Administration Segments in the Infectious Enteritis Treatment Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The infectious enteritis treatment market share growth by the oral segment will be significant during the forecast period. The rapid action of oral rehydration therapy on patients will drive the growth of the market in focus through this segment in the coming years. For instance, it has also been observed that zinc, in conjunction with ORS, is effective in reducing acute diarrhea by 15%-25%.

This report provides an accurate prediction of the contribution of all the segments to the growth of the infectious enteritis treatment market size and actionable market insights on post COVID-19 impact on each segment.

 

Infectious Enteritis Treatment Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 5.09%
Market growth 2022-2026	$ 403.92 million
Market structure	Fragmented
YoY growth (%)	3.52
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 37%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Infectious Enteritis Treatment Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive infectious enteritis treatment market growth during the next five years
• Precise estimation of the infectious enteritis treatment market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the infectious enteritis treatment industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of infectious enteritis treatment market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch